Compare PSIX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | IBRX |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | N/A |
| Metric | PSIX | IBRX |
|---|---|---|
| Price | $66.07 | $2.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $98.76 | $9.71 |
| AVG Volume (30 Days) | 506.2K | ★ 11.5M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.27 | N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $675,481,000.00 | $82,555,000.00 |
| Revenue This Year | $48.27 | $667.18 |
| Revenue Next Year | $14.25 | $88.32 |
| P/E Ratio | $11.97 | ★ N/A |
| Revenue Growth | 54.78 | ★ 1025.95 |
| 52 Week Low | $15.30 | $1.83 |
| 52 Week High | $121.78 | $4.27 |
| Indicator | PSIX | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 49.72 |
| Support Level | $60.49 | $2.17 |
| Resistance Level | $62.26 | $2.50 |
| Average True Range (ATR) | 3.76 | 0.16 |
| MACD | 2.25 | 0.02 |
| Stochastic Oscillator | 94.88 | 39.42 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.